Format

Send to

Choose Destination
Oncotarget. 2016 Mar 29;7(13):16773-92. doi: 10.18632/oncotarget.7780.

Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo.

Author information

1
Department of Oncology, University of Cambridge, Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, U.K.
2
Faculty of Health Sciences, University of Macau, Taipa, Macau SAR.
3
Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
4
IONTAS Ltd., Babraham Research Campus, Cambridge, U.K.
5
Kennedy Institute of Rheumatology, University of Oxford, Headington, Oxford, U.K.
6
Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
7
Danish-Chinese Centre for Proteases and Cancer, Aarhus University, Aarhus, Denmark.
8
Department of Oncology, Odense University Hospital, Odense, Denmark.

Abstract

The membrane-associated matrix metalloproteinase-14, MT1-MMP, has been implicated in pericellular proteolysis with an important role in cellular invasion of collagenous tissues. It is substantially upregulated in various cancers and rheumatoid arthritis, and has been considered as a potential therapeutic target. Here, we report the identification of antibody fragments to MT1-MMP that potently and specifically inhibit its cell surface functions. Lead antibody clones displayed inhibitory activity towards pro-MMP-2 activation, collagen-film degradation and gelatin-film degradation, and were shown to bind to the MT1-MMP catalytic domain outside the active site cleft, inhibiting binding to triple helical collagen. Affinity maturation using CDR3 randomization created a second generation of antibody fragments with dissociation constants down to 0.11 nM, corresponding to an improved affinity of 332-fold with the ability to interfere with cell-surface MT1-MMP functions, displaying IC50 values down to 5 nM. Importantly, the new inhibitors were able to inhibit collagen invasion by tumor-cells in vitro and in vivo primary tumor growth and metastasis of MDA-MB-231 cells in a mouse orthotopic xenograft model. Herein is the first demonstration that an inhibitory antibody targeting sites outside the catalytic cleft of MT1-MMP can effectively abrogate its in vivo activity during tumorigenesis and metastasis.

KEYWORDS:

MT1-MMP; antibody; in vivo targeting; metastasis; non-catalytic sites

PMID:
26934448
PMCID:
PMC4941350
DOI:
10.18632/oncotarget.7780
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center